The FDA enforcement report lists a Class II recall, still ongoing, of compounded semaglutide/cyanocobalamin and tirzepatide/cyanocobalamin injections dispensed in single-use syringes by a US compounding firm. The stated reason is lack of assurance of sterility, related to the formulation with bacteriostatic water and the processing equipment.
This is a US compounding issue rather than a finding against licensed semaglutide or tirzepatide. A Class II recall means use could cause temporary or reversible harm, or that serious harm is unlikely.
The lesson travels. Compounded and unlicensed GLP-1 products are sold widely online, including to patients in India, and quality is not assured. Ask patients on these drugs where they buy them.
- Ask every patient on a GLP-1 or tirzepatide where the product comes from
- Advise licensed, pharmacy-dispensed products over compounded or online-sourced syringes
- Look for injection-site infection in anyone using compounded or unlicensed injections
- The recall concerns one US compounder, not the licensed medicines
Why it matters
Unlicensed GLP-1 supply is a patient-safety question clinicians rarely ask about.
Don't overread it
This is a sterility recall of one compounder's products, not a safety finding about semaglutide or tirzepatide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free